Login / Signup

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Hans J SalwenderUta BertschKatja WeiselJan DuerigChristina KunzAxel BennerIgor W BlauMarc Steffen RaabJens HillengassDirk HoseStefanie HuhnMichael HundemerMindaugas AndrulisAnna JauchAndrea Seidel-GlaetzerHans-Walter LindemannManfred HenselStefan FronhoffsUwe MartensTimon HansenMohammed WattadUllrich GraevenMarkus MunderRoland FenkMathias HaenelChristof ScheidHartmut Goldschmidt
Published in: BMC cancer (2019)
NCT02495922 on June 24th, 2015.
Keyphrases
  • phase iii
  • newly diagnosed
  • open label
  • double blind
  • clinical trial
  • multiple myeloma
  • phase ii
  • placebo controlled
  • study protocol
  • randomized controlled trial
  • stem cell transplantation
  • chronic lymphocytic leukemia